FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246293975> ?p ?o ?g. }

• W2246293975 endingPage "15167" @default.
• W2246293975 startingPage "15167" @default.
• W2246293975 abstract "15167 Background: MMC related TTP/HUS has been reported between 4 and 15%, with a higher incidence in patients receiving cumulative doses of 60 mg or higher. It tends to occur within 4 months of drug administration independently of patients’ cancer status. The ability of MMC to upregulate enzymes relevant for new cytototoxic agents (topoisomerase I for CPT-11 and thymidine phosphorylase for capecitabine) make phamacobiologically based therapeutic combinations including MMC attractive. Methods: All patients (n=100) that participated in four institutional clinical studies from 2000 through 2004 were included. The studies were OSU 9947 (phase I trial of CPT-11 and MMC in solid tumors, n=31) OSU 0151 (phase II trial of CPT-11 and MMC in advanced esophageal and stomach cancer, n=41) OSU 0155 (phase II trial of CPT-11 and MMC in patients with refractory breast cancer, n=26) OSU 0330 (phase I study of capecitabine and MMC in patients with advanced GI tumors n=2). In each study, the maximum cumulative dose of MMC was 36 mg/m 2 . All patients were followed for clinical signs or symptoms of TTP/HUS including the presence of anemia, thrombocytopenia and renal insufficiency and had a thorough review of the peripheral smear. Results: The median cumulative dose was 12 mg/m 2 (range 3–36 mg/m 2 ). No patients met the clinical diagnosis of TTP/HUS except for one patient had anemia, thrombocytopenia and renal insufficiency but did not manifest any other findings consistent with TTP/HUS such as changes in mental status, azotemia or any other clinical symptom. The laboratory abnormalities resolved without intervention within seven days with subsequent continuation on the clinical trial. Conclusions: In this study we have demonstrated that by capping the cumulative dose of MMC to 36 mg/m 2 , the incidence of TTP/HUS is minimal. Furthermore, our preliminary analysis of an additional 100 patients treated with MMC at OSU shows no reported cases of TTP/HUS (additional data will be presented at the meeting). Since MMC is effective in a wide variety of solid tumors including breast, lung and GI malignancies and is inexpensive and easy to administer, further exploration of MMC in the treatment of solid malignancies is indicated including rational combination studies. No significant financial relationships to disclose." @default.
• W2246293975 created "2016-06-24" @default.
• W2246293975 creator A5011944108 @default.
• W2246293975 creator A5015548619 @default.
• W2246293975 creator A5025283014 @default.
• W2246293975 creator A5053638396 @default.
• W2246293975 creator A5074891676 @default.
• W2246293975 creator A5090153404 @default.
• W2246293975 creator A5090194103 @default.
• W2246293975 date "2007-06-20" @default.
• W2246293975 modified "2023-09-25" @default.
• W2246293975 title "A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS)" @default.
• W2246293975 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15167" @default.
• W2246293975 hasPublicationYear "2007" @default.
• W2246293975 type Work @default.
• W2246293975 sameAs 2246293975 @default.
• W2246293975 citedByCount "0" @default.
• W2246293975 crossrefType "journal-article" @default.
• W2246293975 hasAuthorship W2246293975A5011944108 @default.
• W2246293975 hasAuthorship W2246293975A5015548619 @default.
• W2246293975 hasAuthorship W2246293975A5025283014 @default.
• W2246293975 hasAuthorship W2246293975A5053638396 @default.
• W2246293975 hasAuthorship W2246293975A5074891676 @default.
• W2246293975 hasAuthorship W2246293975A5090153404 @default.
• W2246293975 hasAuthorship W2246293975A5090194103 @default.
• W2246293975 hasConcept C121332964 @default.
• W2246293975 hasConcept C121608353 @default.
• W2246293975 hasConcept C126322002 @default.
• W2246293975 hasConcept C141071460 @default.
• W2246293975 hasConcept C142424586 @default.
• W2246293975 hasConcept C151032500 @default.
• W2246293975 hasConcept C2777909004 @default.
• W2246293975 hasConcept C2778248108 @default.
• W2246293975 hasConcept C2778585876 @default.
• W2246293975 hasConcept C2781127562 @default.
• W2246293975 hasConcept C526805850 @default.
• W2246293975 hasConcept C71924100 @default.
• W2246293975 hasConcept C72563966 @default.
• W2246293975 hasConcept C87355193 @default.
• W2246293975 hasConcept C88879693 @default.
• W2246293975 hasConcept C89560881 @default.
• W2246293975 hasConcept C90924648 @default.
• W2246293975 hasConceptScore W2246293975C121332964 @default.
• W2246293975 hasConceptScore W2246293975C121608353 @default.
• W2246293975 hasConceptScore W2246293975C126322002 @default.
• W2246293975 hasConceptScore W2246293975C141071460 @default.
• W2246293975 hasConceptScore W2246293975C142424586 @default.
• W2246293975 hasConceptScore W2246293975C151032500 @default.
• W2246293975 hasConceptScore W2246293975C2777909004 @default.
• W2246293975 hasConceptScore W2246293975C2778248108 @default.
• W2246293975 hasConceptScore W2246293975C2778585876 @default.
• W2246293975 hasConceptScore W2246293975C2781127562 @default.
• W2246293975 hasConceptScore W2246293975C526805850 @default.
• W2246293975 hasConceptScore W2246293975C71924100 @default.
• W2246293975 hasConceptScore W2246293975C72563966 @default.
• W2246293975 hasConceptScore W2246293975C87355193 @default.
• W2246293975 hasConceptScore W2246293975C88879693 @default.
• W2246293975 hasConceptScore W2246293975C89560881 @default.
• W2246293975 hasConceptScore W2246293975C90924648 @default.
• W2246293975 hasIssue "18_suppl" @default.
• W2246293975 hasLocation W22462939751 @default.
• W2246293975 hasOpenAccess W2246293975 @default.
• W2246293975 hasPrimaryLocation W22462939751 @default.
• W2246293975 hasRelatedWork W1966265735 @default.
• W2246293975 hasRelatedWork W2014119546 @default.
• W2246293975 hasRelatedWork W2089886710 @default.
• W2246293975 hasRelatedWork W2436331468 @default.
• W2246293975 hasRelatedWork W2528057197 @default.
• W2246293975 hasRelatedWork W2748980790 @default.
• W2246293975 hasRelatedWork W2792440265 @default.
• W2246293975 hasRelatedWork W2800869282 @default.
• W2246293975 hasRelatedWork W3032477347 @default.
• W2246293975 hasRelatedWork W3122877358 @default.
• W2246293975 hasVolume "25" @default.
• W2246293975 isParatext "false" @default.
• W2246293975 isRetracted "false" @default.
• W2246293975 magId "2246293975" @default.
• W2246293975 workType "article" @default.